|
|
|
|
| LEADER |
01000cam a2200265 4500 |
| 001 |
671147196 |
| 003 |
DE-627 |
| 005 |
20230905072237.0 |
| 007 |
tu |
| 008 |
111101s2012 xxu||||| 00| ||eng c |
| 010 |
|
|
|a 2011044253
|
| 016 |
7 |
|
|a 016120516
|2 UK
|
| 020 |
|
|
|a 9780470878279
|c (hbk.) £80.50
|9 978-0-470-87827-9
|
| 020 |
|
|
|a 0470878274
|c (hbk.) £80.50
|9 0-470-87827-4
|
| 024 |
3 |
|
|a 9780470878279
|
| 035 |
|
|
|a (DE-627)671147196
|
| 035 |
|
|
|a (DE-576)391961721
|
| 035 |
|
|
|a (DE-599)GBV671147196
|
| 035 |
|
|
|a (OCoLC)809828170
|
| 035 |
|
|
|a (OCoLC)809828170
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 044 |
|
|
|c XD-US
|
| 050 |
|
0 |
|a RM301.25
|
| 060 |
|
0 |
|a QV 55
|
| 082 |
0 |
|
|a 338.4/76151
|q LOC
|2 23
|
| 082 |
0 |
|
|a 615.1
|
| 084 |
|
|
|a 15,3
|2 ssgn
|
| 084 |
|
|
|a 44.40
|2 bkl
|
| 084 |
|
|
|a 44.42
|2 bkl
|
| 245 |
1 |
0 |
|a Drug repositioning
|b bringing new life to shelved assets and existing drugs
|c ed. by Michael J. Barratt; Donald E. Frail
|
| 264 |
|
1 |
|a Hoboken, NJ
|b Wiley
|c c 2012
|
| 300 |
|
|
|a XX, 477 S.
|b Ill., graph. Darst.
|c 24 cm
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Includes bibliographical references and index
|
| 505 |
8 |
0 |
|a Drug repositioning : the business case and current strategies to repurpose shelved candidates and marketed drugs / John Arrowsmith and Richard HarrisonOpportunities and challenges associated with developing additional indications for clinical development candidates and marketed drugs / Donald Frail and Michael Barratt -- Clinical and operational considerations in repositioning marketed drugs and drug candidates / Damian O'Connell, David Sequeira, and Maria Miller -- Regulatory considerations and strategies for drug repositioning / Ken Phelps -- Computational and bioinformatic strategies for drug repositioning / Richard Mazzarella and Craig Webb -- Mining scientific and clinical databases to identify novel uses for existing drugs / Christos Andronis ... [et al.] -- Predicting the polypharmacology of drugs : identifying new uses through chemoinformatics, structural informatics and molecular modeling based approaches / Li Xie ... [et al.] -- Systematic phenotypic screening for novel synergistic combinations: a new paradigm for repositioning existing drugs / Margaret Lee -- Phenotypic in vivo screening to identify new, unpredicted indications for existing drugs and drug candidates / Michael Saporito, Christopher Lipinski, and Andrew Reaume -- Old drugs yield new discoveries : examples from the prodrug, chiral switch and site-selective deuteration strategies / Adam Morgan ... [et al.] -- Repurposing drugs for tropical diseases : case studies and open-source screening initiatives / Curtis Chong -- Drug repositioning efforts by non-profit foundations -- Business development strategies in the repositioning industry / Aris Persidis and Elizabeth Stark -- A case study in drug repositioning : Sosei / Akinori Mochizuki and Makiko Aoyama.
|
| 505 |
8 |
0 |
|t Drug repositioning : the business case and current strategies to repurpose shelved candidates and marketed drugs
|r John Arrowsmith and Richard Harrison
|
| 505 |
8 |
0 |
|t Opportunities and challenges associated with developing additional indications for clinical development candidates and marketed drugs
|r Donald Frail and Michael Barratt
|
| 505 |
8 |
0 |
|t Clinical and operational considerations in repositioning marketed drugs and drug candidates
|r Damian O'Connell, David Sequeira, and Maria Miller
|
| 505 |
8 |
0 |
|t Regulatory considerations and strategies for drug repositioning
|r Ken Phelps
|
| 505 |
8 |
0 |
|t Computational and bioinformatic strategies for drug repositioning
|r Richard Mazzarella and Craig Webb
|
| 505 |
8 |
0 |
|t Mining scientific and clinical databases to identify novel uses for existing drugs
|r Christos Andronis ... [et al.]
|
| 505 |
8 |
0 |
|t Predicting the polypharmacology of drugs : identifying new uses through chemoinformatics, structural informatics and molecular modeling based approaches
|r Li Xie ... [et al.]
|
| 505 |
8 |
0 |
|t Systematic phenotypic screening for novel synergistic combinations: a new paradigm for repositioning existing drugs
|r Margaret Lee
|
| 505 |
8 |
0 |
|t Phenotypic in vivo screening to identify new, unpredicted indications for existing drugs and drug candidates
|r Michael Saporito, Christopher Lipinski, and Andrew Reaume
|
| 505 |
8 |
0 |
|t Old drugs yield new discoveries : examples from the prodrug, chiral switch and site-selective deuteration strategies
|r Adam Morgan ... [et al.]
|
| 505 |
8 |
0 |
|t Repurposing drugs for tropical diseases : case studies and open-source screening initiatives
|r Curtis Chong
|
| 505 |
8 |
0 |
|t Drug repositioning efforts by non-profit foundations ; Business development strategies in the repositioning industry
|r Aris Persidis and Elizabeth Stark
|
| 505 |
8 |
0 |
|t A case study in drug repositioning : Sosei
|r Akinori Mochizuki and Makiko Aoyama.
|
| 650 |
|
0 |
|a Drug development
|
| 650 |
|
0 |
|a Drug development
|
| 650 |
|
2 |
|a Drug Repositioning
|
| 650 |
|
2 |
|a Computational Biology
|x methods
|
| 650 |
|
2 |
|a Drug Industry
|x economics
|
| 650 |
|
2 |
|a Pharmaceutical Preparations
|x economics
|
| 653 |
|
4 |
|a Drug development
|
| 653 |
|
4 |
|a Pharmaceutical industry
|
| 689 |
0 |
0 |
|D s
|0 (DE-588)4143176-5
|0 (DE-627)104408812
|0 (DE-576)209724234
|a Arzneimittelentwicklung
|2 gnd
|
| 689 |
0 |
|
|5 (DE-627)
|
| 700 |
1 |
|
|a Barratt, Michael J.
|e hrsg
|4 edt
|
| 700 |
1 |
|
|a Frail, Donald E.
|4 oth
|
| 856 |
4 |
2 |
|u http://www.gbv.de/dms/bs/toc/671147196.pdf
|m V:DE-601
|m B:DE-84
|q pdf/application
|v 2012-08-20
|x Verlag
|y Inhaltsverzeichnis
|3 Inhaltsverzeichnis
|
| 856 |
4 |
2 |
|u https://swbplus.bsz-bw.de/bsz391961721cov.jpg
|m V:DE-576
|m X:wiley
|q image/jpeg
|v 20150129093845
|3 Cover
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a ISIL_DE-84
|
| 912 |
|
|
|a SYSFLAG_1
|
| 912 |
|
|
|a GBV_KXP
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a SSG-OPC-PHA
|
| 912 |
|
|
|a SSG-OPC-DE-84
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a ISIL_DE-9
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a ISIL_DE-14
|
| 935 |
|
|
|i Blocktest
|
| 936 |
b |
k |
|a 44.40
|j Pharmazie
|j Pharmazeutika
|0 (DE-627)106423304
|
| 936 |
b |
k |
|a 44.42
|j Pharmazeutische Chemie
|0 (DE-627)18157179X
|
| 951 |
|
|
|a BO
|
| 953 |
|
|
|2 045F
|a 338.4/76151
|
| 953 |
|
|
|2 045F
|a 615.1
|
| 980 |
|
|
|2 20
|1 01
|x 0084
|b 1275208304
|c 00
|f --%%--
|d 2923-0220
|e --%%--
|j --%%--
|y k
|z 02-08-12
|
| 980 |
|
|
|2 69
|1 01
|x 0009
|b 1319778240
|c 00
|f UB 660
|d 660/VS 5350 B269
|e u
|j --%%--
|y z
|z 23-10-12
|
| 980 |
|
|
|2 2006
|1 01
|x DE-14
|b 3105414886
|c 00
|f --%%--
|d --%%--
|e --%%--
|j --%%--
|y l01
|z 05-08-13
|
| 983 |
|
|
|2 69
|1 00
|x DE-9
|8 00
|a VS 5350
|
| 984 |
|
|
|2 20
|1 01
|x 0084
|a 84$029230220
|
| 984 |
|
|
|2 69
|1 01
|x 0009
|a 9$09374299
|
| 985 |
|
|
|2 69
|1 01
|x 0009
|a 2012.9543
|
